Puma Biotechnology
NasdaqGS:PBYI Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
WA
Consensus Narrative from 3 Analysts
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Key Takeaways Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales. Investment in research and development and cost reduction strategies could enhance product offerings, operational efficiencies, and shareholder value.
View narrativeUS$4.33
FV
33.0% undervalued intrinsic discount-5.30%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative